ライフサイエンスコーパス: furyl

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 A)R antagonist [ZM241385 (4-(2-[7-amino-2-(2-furyl)(1,2,4)triazolo(2,3-a)(1,3,5)triazin-5-ylamino]eth

2 lective AR antagonist, 5-amino-9-chloro-2-(2-furyl)-1, 2, 4-triazolo [1, 5-c] quinazoline (CGS-15943)

3 ylindazole derivative 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1) is an allosteric stimula

4 plying nitrosocysteine, 3-(5-hydroxymethyl-2-furyl)-1-benzyl indazole (YC-1), and 8-bromo cGMP, all t

5 YC-1 [3-(5'-hydroxymethyl-2'furyl)-1-benzyl indazole] is an allosteric activator of

6 YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole], an HIF-1 inhibitor, reduced w

7 rol conditions, YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole], an NO-independent activator o

8 odium nitroprusside or 3-(5'-hydroxymethyl-2'furyl)-1-benzyl-indazole (YC-1).

9 CPP) or the activator 3-(5'-hydroxymethyl-3'-furyl)-1-benzylindazole (YC-1).

10 A(2A) receptor antagonist 4-(2-[7-amino-2-(2-furyl)[1,2,4-triazolo[2,3-a][1,3,5]triazin-5-ylamino]et

11 A(2A) receptor antagonist 4-(2-{7-amino-2-(2-furyl)[1,2,4]-triazolo[2,3-a] [1,3,5]triazin-5-ylamino}e

12 ype-specific antagonists [4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo-[2,3-a][1,3,5]triazin-5-ylamino] e

13 tor antagonist ZM-241385 (4-[2-[7-amino-2-(2-furyl)[1,2,4]triazolo-[2,3-a][1,3,5]triazin-5-ylamino] e

14 nonxanthine adenosine antagonist 9-chloro-2-(furyl)[1,2,4]triazolo[1,5-c]quinazolin-5-amine(6 fold) b

15 selective inverse agonist 4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]eth

16 HIF-inhibitor, YC-1 (3-[5'-Hydroxymethyl-2'-furyl]-1-benzyl-indazole), or vehicle three days before

17 (R)-N-[3-[5-(4-Fluorophenoxy)-2-furyl]-1-methyl-2-propynyl]-N-hydroxyure a (17c) was ide

18 (2A)-selective antagonist 4-(2-[7-amino-2-[2-furyl][1,2, 4]triazolo-[2,3-a][1,3,5] triazin-5-yl-amino

19 gonists including, (125)I-4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo[2,3-a][1,3,5]triazin-5-yl- amino]e

20 ctive A(2A)AR antagonist, 4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo[2,3-a][1,3,5]triazin-5-yl-amino]e

21 ) AR selective antagonist 4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo[2,3-a][1,3,5]triazin-5-yl-amino]e

22 With this approach, N-(4-chlorobenzyl)-3-(2-furyl)-1H-1,2,4-triazol-5-amine (N42FTA) was found to co

23 G 559), and ethyl 2-[3-hydroxy-5-(5-methyl-2-furyl)-2-oxo-4-(2-thienylcarbonyl)-2,5-dihydro-1H-pyrr o

24 olyl, 4-nitrophenyl, 4-diethylaminophenyl, 2-furyl, 2-pyridyl, 2-indolyl, or 2-pyrrolyl) in the prese

25 lpyrrolyl) to regioselective 1,2-addition (2-furyl, 2:1).

26 The synthesis of 7-methoxy-8-(4-methyl-3-furyl)-2H-chromen-2-one, a natural product with antileis

27 The strongest bases are 2,6-bis(3-methoxy-2-furyl)-4-dimethylaminopyridine and 2,6-di(2-dimethylamin

28 5-({[2 (methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (lapatinib), an inhibitor of Er

29 he synthetic collagen-like substrate N-(3-[2-furyl]acryloyl)-Leu-Gly-Pro-Ala, we found that neither t

30 hanistic studies involving deuterium-labeled furyl alcohol suggest that the oxidative rearrangement p

31 BuLi and addition to benzaldehyde provides a furyl alcohol that is converted to 2-phenyl 3-furfural u

32 ducts, these new oxidative rearrangements of furyl alcohols and furyl sulfonamides generate only one

33 zinc reagents (M-R) to 3-furfural provides 3-furyl alcohols in high yields.

34 intramolecular Diels-Alder cyclization of o-furyl(allylamino)arenes.

35 2-Furyl analog 16 showed selective activity against HUVEC,

36 Furyl analogue 36 is the most promising of the series.

37 s possessing the modified bases 6-(2-benzo[b]furyl)- and 6-(2-furyl)pyrrolocytosine (BFpC and FpC) ha

38 = 2- and 3-thiophenyl, 2-benzothiophenyl, 3-furyl, and 5-indolyl) were successfully added to aldehyd

39 xample, those based on p-F-phenyl, naphthyl, furyl, and benzyl moieties are found to require acid cat

40 lied to the cross-coupling of 2-pyrrolyl-, 2-furyl-, and 2-thienylsilanolates.

41 um ylides with acetylenes opens a way to new furyl annelated phosphinolines or unusually substituted

42 ', the cytotoxicity decreases in the order 2-furyl approximately 2-methyl-1-propenyl > or = 2-methylp

43 , (2) stereoselective alpha-methylation, (3) furyl attachment, and (4) introduction of a 16-keto func

44 tial 5-endo-dig cyclization to give a cyclic furyl-Au intermediate.

45 ated reaction, beta-to-Au protonation of the furyl-Au species to give a Au-carbene intermediate compe

46 A sesamol-benzyne cycloaddition with a 3-furyl-benzoate followed by regiospecific lactonization p

47 adenosine receptors indicated that pyridyl, furyl, benzofuryl, and thienyl groups at the 4-position

48 This reaction is found to be general even on furyl carbinols; however, it generates the rearranged po

49 This compound has a furyl-delta-lactone core similar to that of Salvinorin A

50 hyl-3-(methyldithio)furan and bis(2-methyl-3-furyl) disulphide.

51 thyl-3-methyldithiofuran, and bis(2-methyl-3-furyl)disulphide.

52 dG adducts with 8-substituents consisting of furyl ((Fur)dG), phenyl ((Ph)dG), 4-cyanophenyl ((CNPh)d

53 adducts with C(8)-substituents consisting of furyl ((Fur)dG), pyrrolyl ((Pyr)dG), thienyl ((Th)dG), b

54 t of the 6-phenyl ring with a 3-thienyl or 3-furyl group reduced the affinity at A3 receptors by 4- a

55 of this proposed mechanism, we found that 3-furyl imines undergo the addition of organometallic reag

56 g topotecan, 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole (YC-1), and flavopiridol.

57 On the contrary, under gold catalysis furyl-indoles were obtained as exclusive products from N

58 st, 4-(2-[7-amino-2- inverted question mark2-furyl inverted question mark inverted question mark1,2,

59 5-[(4, 5-dichloro-1H-imidazol-1-yl)methyl]-2-furyl inverted question markcarbonyl)-4 methoxybenzene-1

60 ryl-l-cysteine (FFT-S-Cys) and S-(2-methyl-3-furyl)-l-cysteine (MFT-S-Cys) in the Maillard reaction o

61 henyl)-N'-[2-[([5-[(dimethylamino)-methyl]-2-furyl]-m ethyl)-sulfanyl]ethyl]urea) (CAP-1), is well to

62 henyl)-N'-{2-[({5-[(dimethylamino)-methyl]-2-furyl}-methyl)- sulfanyl]ethyl}-urea) (CAP-1) using a co

63 pound 1, nicotinic acid [5-(3-bromophenyl)-2-furyl]methylene-hydrazide; compound 2, 4-fluoro-benzoic

64 benzoic acid [5-(3-trifluoromethyl-phenyl)-2-furyl]-methylene-hydrazide] were selected for further an

65 sn-2 acyl group that incorporates a terminal furyl moiety (oxPC-furan).

66 ts in vivo, the presence of an unsubstituted furyl moiety was a cause of some concern.

67 ities that could arise from an unsubstituted furyl moiety, an optimization effort was undertaken with

68 e first optimized to remove an unsubstituted furyl moiety, with the aim of avoiding the potential met

69 stituted 7-deazapurine derivatives bearing a furyl or ethynyl group at position 7, were significantly

70 tannane precursors for the synthesis of 5-(2-furyl, or 2-thienyl, or 2-pyrrolyl)uracil nucleosides, w

71 o be involved in the insertion of 2 into the furyl-Pd bond.

72 2beta-Carbomethoxy-3beta-(4'-(3-furyl)phenyl)nortropane (1) was synthesized along with t

73 d compounds and then encapsulating bis[tri(2-furyl)phosphine]palladium(II) dichloride in a biocompati

74 ino-7-[2-(4-fluorosulfonyl)phenylethyl]-2-(2-furyl)-pryazolo[4,3-epsilon]-1, 2,4-triazolo[1,5-c]pyrim

75 ioligand [3H]-5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo [4,3-epsilon]-1,2,4-triazolo[1,5-c)pyrim

76 antagonists (7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5 -c]pyrimidine

77 4) but not by 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5- c]pyrimidine

78 or SCH58261 [5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5- c]pyrimidine]

79 ic antagonist 5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo[4,3-epsilon]-1,2,4-triazolo[1,5-c] pyrim

80 Cp-60 (2-amino-6-[(2-aminophenyl)thio]-4-(2-furyl)pyridine-3, 5-dicarbonitrile) and Cp-62 (N'1-( inv

81 modified bases 6-(2-benzo[b]furyl)- and 6-(2-furyl)pyrrolocytosine (BFpC and FpC) have been synthesiz

82 -substitution" (CEIS) in which the gold(III)-furyl sigma-bond produced by furan auration acts as a nu

83 As demonstrated with the beta-(2-furyl)-substituted analogue 1b, beta-aryl-alpha-nitro-al

84 beta-Furyl-substituted anti-alpha-(difluoromethyl)-beta-amino

85 ination of an aza-Achmatowicz oxidation of a furyl-substituted benzenesulfonamide followed by a conju

86 idative rearrangements of furyl alcohols and furyl sulfonamides generate only one regioisomer in each

87 dition of organometallic reagents to provide furyl sulfonamides.

88 anisms of transition-metal free reactions of furyl, thienyl and indolyl trifluoroborates with benzhyd

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。